Compare VYX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | PCRX |
|---|---|---|
| Founded | 1881 | 2006 |
| Country | United States | United States |
| Employees | 13500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | VYX | PCRX |
|---|---|---|
| Price | $6.52 | $23.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $13.67 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 2.2M | 516.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $8.54 |
| P/E Ratio | ★ N/A | $336.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $6.02 | $18.80 |
| 52 Week High | $14.67 | $27.64 |
| Indicator | VYX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 49.85 |
| Support Level | $6.21 | $22.13 |
| Resistance Level | $7.26 | $24.20 |
| Average True Range (ATR) | 0.42 | 1.02 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 12.78 | 42.93 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.